153 related articles for article (PubMed ID: 18025844)
1. Neuroendocrine differentiation in prostate cancer: from lab to bedside.
Cindolo L; Cantile M; Vacherot F; Terry S; de la Taille A
Urol Int; 2007; 79(4):287-96. PubMed ID: 18025844
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.
Vashchenko N; Abrahamsson PA
Eur Urol; 2005 Feb; 47(2):147-55. PubMed ID: 15661408
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in prostatic carcinoma: an update.
di Sant'Agnese PA
Prostate Suppl; 1998; 8():74-9. PubMed ID: 9690666
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
5. [Interleukin-6 implication in prostate cancer].
Cabrespine A; Bay JO; Verrelle P; Morel L
Bull Cancer; 2007 Jul; 94(7 Suppl):F29-34. PubMed ID: 17845991
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of neuroendocrine differentiation in prostate cancer.
Nelson EC; Cambio AJ; Yang JC; Ok JH; Lara PN; Evans CP
Prostate Cancer Prostatic Dis; 2007; 10(1):6-14. PubMed ID: 17075603
[TBL] [Abstract][Full Text] [Related]
8. Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
Gross M; Ramirez C; Luthringer D; Nepomuceno E; Vollmer R; Burchette J; Freedland SJ
Prostate; 2009 Apr; 69(5):520-7. PubMed ID: 19107851
[TBL] [Abstract][Full Text] [Related]
9. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
10. Unusual prostate carcinoma characterized by extensive metastasis, significantly increased serum level of prostatic-specific antigen,and neuroendocrine differentiation: a case report.
Hu YX; Ye J; Jiang Y; Zhang QF; Wu YL; Chen YY
Chin Med J (Engl); 2005 Feb; 118(3):258-61. PubMed ID: 15740661
[No Abstract] [Full Text] [Related]
11. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
13. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine features of prostatic tumors: state of the art].
Turitto G; Frattolillo A; Iodice P; Auriemma A; Tortoriello A; di Grazia M; Iaffaioli RV
Recenti Prog Med; 2003 Dec; 94(12):568-72. PubMed ID: 14974154
[TBL] [Abstract][Full Text] [Related]
15. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer.
Aprikian AG; Han K; Guy L; Landry F; Begin LR; Chevalier S
Prostate Suppl; 1998; 8():52-61. PubMed ID: 9690664
[No Abstract] [Full Text] [Related]
17. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
19. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
[TBL] [Abstract][Full Text] [Related]
20. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
